Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Versus Observation in Patients Who Achieve a Chemotherapy-induced Remission

NCT03059485 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.

NCT NCT03059485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03059485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Versus Observation in Patients Who Achieve a Chemotherapy-induced Remission
Lead sponsor
Beth Israel Deaconess Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 1, 2017
Completion date
June 4, 2027
Enrollment
82 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia